The introduction of human heavy and light chain transgene loci into an engineered mouse background results in the production, in response to antigen challenge, of either a single class of conventional human antibodies carrying a specific set of effector function (eg IgG or IgA), or multiple classes of antibodies (eg.IgM and IgG), dependent on the design of the introduced heavy chain immunoglobulin loci. Antigen specific H2L2 monoclonal antibodies can be recovered using standard hybridoma technology.
Harbour’s H2L2 mice technology is covered by US Patent #9,131,669 and several international issued and pending patent rights.
Transgenic animals have been challenged with more than 10 different antigens, 2 of which had proved challenging in other platforms
Immune response comparable to normal mice such as Balb/c
MAbs have been successfully generated against all 10 targets spanning multiple epitopes within the protein of interest
H2L2 transgenic animals display normal antibody maturation in vivo
H2L2 Antibody Characterization